Image may be NSFW.
Clik here to view.
Glenmark Pharmaceuticals S.A., a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals Ltd., announced that GBR 900, a novel monoclonal antibody is entering human trials. GBR 900 targets TrkA, a receptor for nerve growth factor (NGF) involved in chronic pain signaling.
In 2010, Glenmark gained an exclusive worldwide license from Lay Line Genomics S.p.A. (Italy) for anti-TrkA antibodies and their entire intellectual property portfolio in the TrkA field. GBR 900 is the optimized anti-TrkA antibody emerging from this exclusive worldwide license.
read all at
http://www.dddmag.com/news/2014/04/glenmark-kicks-monoclonal-antibody-pain-studies
Glenmark Kicks Off Monoclonal Antibody Pain Studies
Image may be NSFW.
Clik here to view.
Glenmark Pharmaceuticals today said its novel monoclonal antibody for potential treatment of chronic pain is entering human trials.
http://economictimes.indiatimes.com/articleshow/34377930.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
Filed under: ANTIBODIES, GLENMARK, glenmark, Monoclonal antibody, PHASE1 Tagged: gbr 900, GLENMARK, PHASE 1 Image may be NSFW.
Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
Image may be NSFW.Clik here to view.
